<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03187626</url>
  </required_header>
  <id_info>
    <org_study_id>P160404</org_study_id>
    <nct_id>NCT03187626</nct_id>
  </id_info>
  <brief_title>Efficacy of an Intra-articular Injection of Botulinum Toxin A Associated With Splinting for Base-of-thumb Osteoarthritis</brief_title>
  <acronym>RHIBOT</acronym>
  <official_title>Short-term Efficacy of a Single Ultrasound-guided Intra-articular Injection of Botulinum Toxin A Associated With Splinting for Base-of-thumb Osteoarthritis: a Randomized Controlled Double-blind Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Recherche Clinique Paris Descartes Necker Cochin Sainte Anne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to determine whether a single ultrasound-guided&#xD;
      intra-articular injection of botulinum toxin A associated to splinting is effective in&#xD;
      reducing pain at 3 months in base-of-thumb osteoarthritis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Base-of-thumb osteoarthritis is a common condition affecting middle-age persons.&#xD;
      Base-of-thumb osteoarthritis induces pain and hand-specific limitations in activities. For&#xD;
      short and midterm effects, therapeutic options usually include splinting, exercise therapy&#xD;
      and intra-articular injections of glucocorticoids or hyaluronic acid. However, evidence of&#xD;
      efficacy of intra-articular therapies in base-of-thumb osteoarthritis and international&#xD;
      guidelines are inconsistent. Recently, the use of intra-articular botulinum toxin A as a pain&#xD;
      killer has raised intense interest. The exact mechanisms of pain modulation by botulinum&#xD;
      toxin A in osteoarthritis are unclear. It has been suggested that botulinum toxin A could&#xD;
      directly reduce peripheral sensitization and indirectly reduce central sensitization. Indeed,&#xD;
      recent studies suggest an inhibitory role of botulinum toxin A on the release of mediators&#xD;
      involved in nociception, such as P substance, calcitonin gene-related peptide and glutamate.&#xD;
      Open and randomized controlled trials of botulinum toxin A in knee osteoarthritis support&#xD;
      short to mid-term positive clinical effects on pain. However, no study has reported results&#xD;
      for base-of-thumb osteoarthritis&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 29, 2018</start_date>
  <completion_date type="Actual">April 23, 2021</completion_date>
  <primary_completion_date type="Actual">February 16, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in base-of-thumb pain 3 months post-injection</measure>
    <time_frame>3 months post injection</time_frame>
    <description>Mean change from baseline in average base-of-thumb pain intensity in the previous 48 hrs on a self-administered 11-point pain numeric rating scale (0 no pain - 100 maximal pain)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in base-of-thumb pain 1 month post-injection</measure>
    <time_frame>1 month post injection</time_frame>
    <description>Mean change from baseline in average base-of-thumb pain intensity in the previous 48 hrs on a self-administered 11-point pain numeric rating scale (0 no pain - 100 maximal pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in base-of-thumb pain 6 months post-injection</measure>
    <time_frame>6 months post injection</time_frame>
    <description>Mean change from baseline in average base-of-thumb pain intensity in the previous 48 hrs on a self-administered 11-point pain numeric rating scale (0 no pain - 100 maximal pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hand function 3 months post-injection</measure>
    <time_frame>3 months post injection</time_frame>
    <description>Mean change from baseline in average hand-specific limitations in activities in the previous 2 weeks on the self-administered Cochin Hand Function Scale (0 no limitations - 90 maximal limitations)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hand function 6 months post-injection</measure>
    <time_frame>6 months post injection</time_frame>
    <description>Mean change from baseline in average hand-specific limitations in activities in the previous 2 weeks on the self-administered Cochin Hand Function Scale (0 no limitations - 90 maximal limitations)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in patient's global assessment 3 months post-injection</measure>
    <time_frame>3 months post-injection</time_frame>
    <description>Mean change from baseline in patient's global assessment on a self-administered 11-point numeric rating scale (0 worst possible - 100 best possible)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in patient's global assessment 6 months post-injection</measure>
    <time_frame>6 months post-injection</time_frame>
    <description>Mean change from baseline in patient's global assessment on a self-administered 11-point numeric rating scale (0 worst possible - 100 best possible)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of OARSI responders 3 months post-injection</measure>
    <time_frame>3 months post-injection</time_frame>
    <description>OARSI response is defined as an improvement in pain (0 to 100 numeric rating scale) or in function (0 to 90 Cochin Hand Function Scale) ≥ 50% and absolute change ≥ 20/100 on pain numeric rating scale or ≥ 9/90 on Cochin Hand Function Scale respectively , or improvement in at least 2 of the 3 following items: 1/ pain ≥ 20% and absolute change ≥ 10/100, 2/ function ≥ 20% and absolute change ≥ 9/90, 3/ patient's global assessment (0 to 100 numeric rating scale) ≥ 20% and absolute change ≥ 10/100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of OARSI responders 6 months post-injection</measure>
    <time_frame>6 months post-injection</time_frame>
    <description>OARSI response is defined as an improvement in pain (0 to 100 numeric rating scale) or in function (0 to 90 Cochin Hand Function Scale) ≥ 50% and absolute change ≥ 20/100 on pain numeric rating scale or ≥ 9/90 on Cochin Hand Function Scale respectively , or improvement in at least 2 of the 3 following items: 1/ pain ≥ 20% and absolute change ≥ 10/100, 2/ function ≥ 20% and absolute change ≥ 9/90, 3/ patient's global assessment (0 to 100 numeric rating scale) ≥ 20% and absolute change ≥ 10/100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesics consumption at 3 months</measure>
    <time_frame>from injection to 3 months post-injection</time_frame>
    <description>Self-reported consumption of analgesics (non-opioid, weak and strong opioids) using a self-administered 4-class scale (never; several times a month; several times a week; daily)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesics consumption at 6 months</measure>
    <time_frame>from 3 to 6 months post-injection</time_frame>
    <description>Self-reported consumption of analgesics (non-opioid, weak and strong opioids) using a self-administered 4-class scale (never; several times a month; several times a week; daily)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-steroidal anti-inflammatory drugs consumption at 3 months</measure>
    <time_frame>from injection to 3 months post-injection</time_frame>
    <description>Self-reported consumption of non-steroidal anti-inflammatory drugs using a self-administered 4-class scale (never; several times a month; several times a week; daily)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-steroidal anti-inflammatory drugs consumption at 6 months</measure>
    <time_frame>from 3 to 6 months post-injection</time_frame>
    <description>Self-reported consumption of non-steroidal anti-inflammatory drugs using a self-administered 4-class scale (never; several times a month; several times a week; daily)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Base-of-thumb Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Intra-articular botulinum toxin A and splinting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ultrasound-guided injection of 50 Allergan Unities of botulinum toxin A (Botox®, Allergan) resuspended in 1 ml of saline in the trapeziometacarpal joint and custom-made thermoformed plastic splint to be worn for 48 hours after intra-articular injection then nightly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intra-articular saline and splinting</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ultrasound-guided injection of 1 ml of saline in the trapeziometacarpal joint and custom-made thermoformed plastic splint to be worn for 48 hours after intra-articular injection then nightly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>botulinum toxin A</intervention_name>
    <description>Ultrasound-guided injection of 50 Allergan Unities of botulinum toxin A (Botox®, Allergan) resuspended in 1 ml of saline in the trapeziometacarpal joint and custom-made thermoformed plastic splint to be worn for 48 hours after intra-articular injection then nightly</description>
    <arm_group_label>Intra-articular botulinum toxin A and splinting</arm_group_label>
    <other_name>Botox®</other_name>
    <other_name>Allergan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>saline</intervention_name>
    <description>Ultrasound-guided injection of 1 ml of saline in the trapeziometacarpal joint and custom-made thermoformed plastic splint to be worn for 48 hours after intra-articular injection then nightly</description>
    <arm_group_label>Intra-articular saline and splinting</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years old&#xD;
&#xD;
          -  Pain intensity on a self-administered 11-point pain numeric rating scale ≥ 30&#xD;
&#xD;
          -  Pain involving the base-of-thumb&#xD;
&#xD;
          -  X-ray evidence of base-of-thumb osteoarthritis with at least 2 of the 4 following&#xD;
             items involving the trapeziometacarpal joint : osteophytes, joint space narrowing,&#xD;
             subchondral bone sclerosis or subchondral cysts&#xD;
&#xD;
          -  1990 American College of Rheumatology classification criteria for hand osteoarthritis&#xD;
             adapted to base-of-thumb osteoarthritis&#xD;
&#xD;
          -  Medical examination&#xD;
&#xD;
          -  Written consent&#xD;
&#xD;
          -  Health insurance&#xD;
&#xD;
          -  For women of childbearing age, a negative urinary pregnancy test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of thumb surgery&#xD;
&#xD;
          -  History of inflammatory or crystal-associated rheumatic disease&#xD;
&#xD;
          -  Neurological disorders involving the hands other than carpien canal syndrom&#xD;
&#xD;
          -  Collagen disorders involving the hands : Dupuytren, Marfan or Ehlers-Danlos diseases&#xD;
&#xD;
          -  Osteoarthritis predominating at the scaphotrapezial joint on X-Ray&#xD;
&#xD;
          -  Hand or wrist trauma ≤ 2 months&#xD;
&#xD;
          -  Hand or wrist intra-articular injections ≤ 2 months&#xD;
&#xD;
          -  Contra-indication to botulinum toxin A injection or to splinting&#xD;
&#xD;
          -  Cognitive or behavioral disorders making the assessment impossible&#xD;
&#xD;
          -  Participant unable to speak, read and write french&#xD;
&#xD;
          -  Bilateral BTOA without predominant symptomatic side&#xD;
&#xD;
          -  Pregnancy and breast feeding&#xD;
&#xD;
          -  Persons referred to in Articles L 1121-5; 6; 8; 9 of the Public Health Code (protected&#xD;
             minors or adults, guardianship or trusteeship, etc.)&#xD;
&#xD;
          -  Patient with epilepsy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François RANNOU, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>AP-HP , université Paris Descartes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christelle NGUYEN, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AP-HP, université Paris Descartes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assistance Publique - Hôpitaux de Paris, Service de Rééducation et de Réadaptation de l'Appareil Locomoteur et des Pathologies du Rachis, Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 13, 2017</study_first_submitted>
  <study_first_submitted_qc>June 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 15, 2017</study_first_posted>
  <last_update_submitted>June 26, 2021</last_update_submitted>
  <last_update_submitted_qc>June 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Base-of-thumb osteoarthritis</keyword>
  <keyword>Botulinum toxin A</keyword>
  <keyword>Intra-articular therapy</keyword>
  <keyword>Randomized trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

